Effect of Modified Erchentang on NLRP3 Inflammasome Expression in Peripheral Blood Mononuclear Cells (PBMCs) of Rats with Chronic Obstructive Pulmonary Disease
10.13422/j.cnki.syfjx.20192204
- VernacularTitle: 二陈汤加味通过抑制NLRP3通路对慢性阻塞性肺疾病的防治作用
- Author:
Li-zhi SHANG
1
;
Shu JI
1
;
Guo-qiang WANG
1
;
Xiao-hui CHEN
1
;
Hong-wei WANG
1
;
Long-tao SHI
1
;
Guang-yuan ZHANG
1
;
Yao-yang LI
1
;
Li-li XU
1
Author Information
1. Henan University of Chinese Medicine, Zhengzhou 450046, China
- Publication Type:Research Article
- Keywords:
chronic obstructive pulmonary disease(COPD);
Erchentang;
Nod-like receptor protein 3(NLRP3)inflammasome;
interleukin-1β(IL-1β);
interleukin-18(IL-18)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(23):56-64
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the effect of modified Erchentang on the expressions of NLRP3 inflammasome genes in peripheral blood mononuclear cells (PBMCs) and the levels of interleukin-1β(IL-1β)and interleukin-18(IL-18)and chemokine8 (CXCL8) in lung tissue of rats with chronic obstructive pulmonary disease (COPD), in order to explore the molecular mechanism of modified Erchentang against inflammation of COPD. Method: Forty SD rats were randomly divided into normal control group, model group, MCC950 (NLRP3 inhibitor) group and modified Erchentang group. The COPD model of rats was prepared by using cigarette smoke and dripping with lipopolysaccharide (LPS). During the modeling period (from the 1st to the 30th day), the MCC950 group received a single intraperitoneal injection with 60 mg · kg-1 on the first day of the experiment,and the modified Erchentang group was given intragastric administration with 10 g · kg-1, once every 2 days. From the 31st to the 45th day, the MCC950 group was intraperitoneally injected with 3 mg · kg-1, once every 2 days, the modified Erchentang group was given intragastric administration with 10 g · kg-1, twice a day, and the normal group and the model group received normal saline (NS) with 10 g · kg-1, twice a day. The levels of interleukin-1β(IL-1β), interleukin-18(IL-18) and chemokine8 (CXCL8) in rats lung tissue homogenate were detected by enzyme-linked immunosorbent assay (ELISA). The expressions of NLRP3, apoptosis-associated speck-like protein (ASC) and cysteinyl aspartate specific proteinase-1 (Caspase-1) mRNA in PBMCs were measured by Real-time fluorescence quantitative PCR (Real-time PCR). Western blot was used to detect the levels of NLRP3, ASC and Caspase-1 proteins in PBMCs. Immunohistochemical(IHC)method was used to detect the expressions of NLRP3, ASC and Caspase-1 proteins in lung tissues. Result: The expressions of NLRP3, ASC and Caspase-1 mRNA and protein were increased significantly (P<0.01) in model group compared with normal group. Compared with model group, the expressions of NLRP3, ASC and Caspase-1 mRNA and protein were decreased significantly in PBMCs (P<0.05,P<0.01) of modified Erchentang group. The levels of IL-18, IL-1β and CXCL8 in lung tissue homogenate in model group were significantly higher than those in the control group. However, compared with model group, the levels of IL-18, IL-1β and CXCL8 were decreased significantly (P<0.05,P<0.01) in modified Erchentang group. Conclusion: NLRP3 inflammasome is involved in the inflammatory response in COPD rats. Modified Erchentang may inhibit the inflammatory response of COPD effectively. The mechanism may be correlated with the reduction of NLRP3, ASC and Caspase-1 gene expressions, and the inhibition of the release of IL-18, IL-1β and CXCL8.
